Please assess the completion status of the following clinical trial:

Trial Title: 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* T-ALL; T-NHL~* age \>= 18 years~* cytological treatment failure / relapse~* molecular treatment failure / relapse~* no promising therapy alternatives with approved medication available~* no CNS-manifestation, requiring intrathecal therapy or CNS-radiation~* no convulsive disease or neurotoxicity \> grade III in patients history~* written informed consent~* no cytostatic therapy in the last 10 days~* no pregnancy or breastfeeding~* effective contraception~* recovery of toxicities of previous chemotherapy - except leukemia- related changes like bone marrow suppression or pathological transaminases in liver manifestation~Exclusion Criteria:~* Severe psychiatric illness~* uncontrolled or severe cardiac disease or infection~* active secondary neoplasms - except skin cancer (no melanoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Nelarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).